Leveraging Mindsets for the Improvement of Health and Well-Being in Cancer Patients

Inclusion Criteria

• Patients diagnosed with lung cancer, breast cancer, gastrointestinal (GI)/colorectal cancer, or lymphoma to be treated with curative intent will be eligible for this study
• Participants will be recruited if they are receiving at least one course of systemic treatment. As we are recruiting participants near the point of diagnosis, we will target individuals who have not received prior therapy for cancer
• We will only recruit patients who are fluent in English and are without cognitive impairment.
• Neither Eastern Cooperative Oncology Group (ECOG) or Karnofsky performance status will be employed
• Ability to understand and willingness to sign a written informed consent document is required for participation in this study
• Treatment plan includes course of systemic treatment involving no less than 4 and no more than 12 infusions

Exclusion Criteria

• Surgical procedures, if applicable, must take place either before the initiation of systemic treatment or after the last infusion
• There are no restrictions regarding the use of other investigational agents; however, use of any investigational agents will be recorded
• No active major mental health diagnoses including severe depression, severe anxiety, bipolar/manic depressive disorder, post-traumatic stress disorder, schizophrenia, or any psychotic disorder. Patients with mild depression or anxiety, or depression or anxiety that is well managed with treatment, will not be excluded
• Pregnant/nursing patients will not be excluded from the study
• Patients with a previous diagnosis of cancer (cancer survivors) will be excluded from this study. Cancer survivors may already have preconceived notions about the nature of a cancer diagnosis and the course of treatment, and therefore may not respond to our intervention in the same way as individuals who are encountering a cancer diagnosis for the first time. * Patients who are human immunodeficiency virus (HIV)-positive will not be excluded
• Patients who have major comorbidities that would substantially reduce life expectancy despite successful cancer treatment (i.e., comorbid end stage heart disease or kidney disease) will be excluded from this study